Discovery improves understanding of the cause of allergic asthma and may serve as an early diagnostic marker / Publication in Nature Immunology
When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies.
However, if these regulatory mechanisms malfunction the cells of the immune system attack innocuous substances which enter the body from the environment, ultimately leading to the development of atopic diseases such as allergic asthma. In western countries, asthma is the most common chronic disease in children under the age of 15 years.
Professor Tobias Bopp, Professor Edgar Schmitt, and Dr. Alexander Ulges of the Institute of Immunology at the University Medical Center of Johannes Gutenberg University Mainz (JGU) have made major progress towards explaining the underlying mechanisms by identifying a previously unknown sub-population of regulatory T cells.
The researchers discovered that this Treg cell type plays a decisive role in the development and manifestation of allergic asthma. They thus conclude that an increased level of this Treg cell population could serve as an early diagnostic indicator of a predisposition to allergic diseases. The results of the research undertaken by Bopp and his colleagues appear in the specialist journal Nature Immunology.
Their investigations showed that the Treg cell sub-population they discovered can be distinguished by a molecule known as immunoglobulin-like transcript 3 (ILT3), a protein which is expressed on the surface of these cells. This molecule probably serves as a “brake” leading to inactivation of the main function of Treg cells, which is to prevent excessive immune reactions.
"This finding is of considerable importance. It is the first time we have identified a sub-population of regulatory T cells whose ability to suppress immunological reactions can be influenced," explained Professor Tobias Bopp. In addition, the research team discovered that the development of ILT3 in Treg cells is regulated by protein kinase CK2. In general, protein kinases are mainly responsible for the transmission of extra-cellular signals within cells.
"So we now know not only how the newly discovered Treg cell sub-population is generated, but also how it can be manipulated. This helps us to better understand how allergic asthma develops and how it can be diagnosed earlier," concluded Bopp.
"This insight has massive potential, not only when it comes to the treatment of allergies. This could also represent an important starting point for the development of innovative approaches to the therapy of autoimmune diseases, tumors, and chronic infections. These are exactly the research areas on which we are currently focusing at the Research Center for Immunotherapy," emphasized Professor Hansjörg Schild, head of the research center at Mainz University.
A. Ulges et al., Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo, Nature Immunology, 19 January 2015, DOI:10.1038/ni.3083
Professor Dr. Tobias Bopp
Institute of Immunology at the Mainz University Medical Center and Research Center for Immunotherapy of Johannes Gutenberg University Mainz
55131 Mainz, GERMANY
phone +49 6131 17 6175
Oliver Kreft, Press and Public Relations, Mainz University Medical Center,
phone +49 6131 17-7424, fax +49 6131 17-3496, e-mail: firstname.lastname@example.org
http://www.uni-mainz.de/presse/18045_ENG_HTML.php - press release ;
http://www.nature.com/ni/journal/vaop/ncurrent/full/ni.3083.html - original publication in NATURE IMMUNOLOGY
Petra Giegerich | idw - Informationsdienst Wissenschaft
Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University
Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
23.08.2017 | Materials Sciences
23.08.2017 | Automotive Engineering
23.08.2017 | Life Sciences